Journal of Pharmaceutical Sciences & Emerging DrugsISSN: 2380-9477

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The Role of Antibody-Drug Conjugates in Immuno-Oncology: Combination Approaches for Improved Responses

Antibody-Drug Conjugates (ADCs) have emerged as a promising class of therapeutics in immuno-oncology, combining the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. This brief study explores the role of ADCs in immuno-oncology, focusing on their potential for combination approaches to enhance therapeutic responses. By leveraging the unique characteristics of ADCs and synergizing with other immuno-oncology modalities, such as immune checkpoint inhibitors and adoptive cell therapies, ADCs hold the promise of improving outcomes for cancer patients

Special Features

Full Text


Track Your Manuscript

Media Partners